ConductScience.org, home

Paper39713612

Magnetic Nanocarriers for pH/GSH/NIR Triple-Responsive Drug Release and Synergistic Therapy in Tumor Cells.

Zhang D and 8 others. ACS Omega, 2024. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Magnetic Nanocarriers for pH/GSH/NIR Triple-Responsive Drug Release and Synergistic Therapy in Tumor Cells. Papers, record 39713612. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39713612

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Magnetic Nanocarriers for pH/GSH/NIR Triple-Responsive Drug Release and Synergistic Therapy in Tumor Cells.
PubMed
Journal
ACS Omega
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
1
iCite
Relative citation ratio, by iCite
0.18, provisional
iCite
Revised in PubMed
2025-01-04
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhang DDi
2Wei WWanyu
3Xie TTianxiang
4Zhou XXue
5He XXu
6Qiao JJie
7Guo RRui
8Jin GGang
9Li NNingbohttps://orcid.org/0000-0002-7456-6272

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References29

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136812969Synthesis of chitosan succinate-g-amine functionalized mesoporous silica: Inorganic-organic nanohybrid for antibacterial assessment, antioxidant activity and pH-controlled drug delivery.Int J Biol Macromol2023https://conductscience.org/library/papers/36812969PubMed
235642539Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?Chem Soc Rev2022https://conductscience.org/library/papers/35642539PubMed
332254406A dual-responsive, hyaluronic acid targeted drug delivery system based on hollow mesoporous silica nanoparticles for cancer therapy.J Mater Chem B2018https://conductscience.org/library/papers/32254406PubMed
436414398Multifunctional Superparticles for Magnetically Targeted NIR-II Imaging and Photodynamic Therapy.Adv Sci (Weinh)2023https://conductscience.org/library/papers/36414398PubMed
533538338Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin2021https://conductscience.org/library/papers/33538338PubMed
635798082Chitosan-modified nanocarriers as carriers for anticancer drug delivery: Promises and hurdles.Int J Biol Macromol2022https://conductscience.org/library/papers/35798082PubMed
736632234Nanomaterial-based CT contrast agents and their applications in image-guided therapy.Theranostics2023https://conductscience.org/library/papers/36632234PubMed
836944197Synthesis of Monodispersed Hollow Mesoporous Organosilica and Silica Nanoparticles with Controllable Shell Thickness Using Soft and Hard Templates.Langmuir2023https://conductscience.org/library/papers/36944197PubMed
935259519TRAIL-modified, doxorubicin-embedded periodic mesoporous organosilica nanoparticles for targeted drug delivery and efficient antitumor immunotherapy.Acta Biomater2022https://conductscience.org/library/papers/35259519PubMed
1028274115Progress in Nanotheranostics Based on Mesoporous Silica Nanomaterial Platforms.ACS Appl Mater Interfaces2017https://conductscience.org/library/papers/28274115PubMed
1134738816Intelligent Pore Switch of Hollow Mesoporous Organosilica Nanoparticles for High Contrast Magnetic Resonance Imaging and Tumor-Specific Chemotherapy.Nano Lett2021https://conductscience.org/library/papers/34738816PubMed
1235025274Label-Free Fluorescent Mesoporous Bioglass for Drug Delivery, Optical Triple-Mode Imaging, and Photothermal/Photodynamic Synergistic Cancer Therapy.ACS Appl Bio Mater2020https://conductscience.org/library/papers/35025274PubMed
1335944586Multifunctional plasmonic-magnetic nanoparticles for bioimaging and hyperthermia.Adv Drug Deliv Rev2022https://conductscience.org/library/papers/35944586PubMed
1436874010Nanoparticle drug delivery systems for synergistic delivery of tumor therapy.Front Pharmacol2023https://conductscience.org/library/papers/36874010PubMed
1537137353Lutein-loaded chitosan/alginate-coated Fe3O4 nanoparticles as effective targeted carriers for breast cancer treatment.Int J Biol Macromol2023https://conductscience.org/library/papers/37137353PubMed
1631761234ZnO capped flower-like porous carbon-Fe3O4 composite as carrier for bi-triggered drug delivery.Mater Sci Eng C Mater Biol Appl2020https://conductscience.org/library/papers/31761234PubMed
1736703527Magnetic Targeting Nanocarriers Combined with Focusing Ultrasound for Enhanced Intracerebral Hemorrhage Therapy.Small2023https://conductscience.org/library/papers/36703527PubMed
1830539634Combinatory Cancer Therapeutics with Nanoceria-Capped Mesoporous Silica Nanocarriers through pH-triggered Drug Release and Redox Activity.ACS Appl Mater Interfaces2019https://conductscience.org/library/papers/30539634PubMed
1932797715Targeted Theranostic Nano Vehicle Endorsed with Self-Destruction and Immunostimulatory Features to Circumvent Drug Resistance and Wipe-Out Tumor Reinitiating Cancer Stem Cells.Small2020https://conductscience.org/library/papers/32797715PubMed
2032739773SiO2-coated magnetic nano-Fe3O4 photosensitizer for synergistic tumour-targeted chemo-photothermal therapy.Colloids Surf B Biointerfaces2020https://conductscience.org/library/papers/32739773PubMed

See all 29 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn PapersSource
42978988Magnetic nanoplatforms at the tumor redox interface: from catalytic ROS amplification to ferroptosis and multimodal cancer therapy.Front Oncol2026https://conductscience.org/library/papers/42978988PubMed
42662568Mechanisms and therapeutic design of stimuli-responsive vesicular nanocarriers for melanoma.Int J Pharm X2026https://conductscience.org/library/papers/42662568PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39713612

GET https://conductscience.org/api/papers/v1/39713612/references?page=2